NEW YORK – Ann Arbor, Michigan-based Strata Oncology announced on Tuesday that it has partnered with Elevation Oncology, a New York-based precision oncology startup, to genomically profile and identify patients eligible for enrollment in a Phase II study for the investigational drug seribantumab.